peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

ACTH analog

Semax

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Mechanism

The spinal cord injury severity was operationalized by clip force: 20-g for mild injury and 35-g for severe injury.

Sources[1]pubmedEffect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats).created mild SCI models with 20-g, and severe SCI with 35-g aneurysm clips.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “created mild SCI models with 20-g, and severe SCI with 35-g aneurysm clips.”

    Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats). · METHOD

    pubmed:41179234:0fed237ace6f:0fed237ace6f

What has been studied?

What the evidence says.

Study findings

In the severe injury condition, semax (ACTH4-10) raised IL-4 and IL-10 levels at 6 hours compared with placebo.

Sources[1]pubmedEffect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats).and IL-4, IL-10 at 6 hours compared with the placebo group.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “and IL-4, IL-10 at 6 hours compared with the placebo group.”

    Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats). · RESULTS

    pubmed:41179234:0fed237ace6f:0fed237ace6f

Study findings

For the severe SCI condition, semax (ACTH4-10) produced higher IL-10 and IL-13 levels at 3 hours compared with 0.9% NaCl placebo.

Sources[1]pubmedEffect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats).Rats with severe compression in ACTH4-10group showed greater levels of IL-10, IL-13 at 3 hours
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Rats with severe compression in ACTH4-10group showed greater levels of IL-10, IL-13 at 3 hours”

    Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats). · RESULTS

    pubmed:41179234:0fed237ace6f:0fed237ace6f

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, regulatory, safety
  • 20 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (13), assurance_score_below_0.72 (3), current_regulatory_source_required (4), extraction_ambiguity (17), high_risk_requires_regulatory_or_two_independent_sources (6), no_direct_support (16)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats). ↗

    pubmed · published 2023-01-01 · retrieved 2026-08-29T08:37:13Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-29T08:37:13Z

33983fddb4d029977bcff6569060b7db84b486e8cdd06b32a0e5a7cd4be1b1d9